Yves Leblanc

This inventor holds 40 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Frosst Canada, Inc., Merck Frosst Canada & Co., Constellation Pharmaceuticals, Inc.. Active years: 1993-2022.

USPTO Granted Patents = 40 (Patent Applications = 8)

% Patents Active = 72.5

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 6.3

ph-index = 12

Forward Citations = 1,483(Granted Patents)

Location History:

Quebec, CA (2014)
Kirkland, CA (1993 - 2022)

Company Filing History:

18 out of 212

Merck Frosst Canada, Inc.

patents

12 out of 80

Merck Frosst Canada & Co.

patents

4 out of 56

Constellation Pharmaceuticals, Inc.

patents

4. 3 out of 108

Infinity Pharmaceuticals, Inc.

Cantero Therapeutics, Inc.

patent

8. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 1993-2022

Loading Chart...

Areas of Expertise:

COX-2 Inhibitors

PTP-1B Inhibitors

Receptor Antagonists

Kinase Inhibitors

Therapeutic Compounds

Fatty Acid Amide Hydrolase

Bromodomain Inhibitors

Neurodegenerative Diseases

Azaindole Derivatives

Triazole Glycolate

Phenyl Heterocycles

Leukotriene Antagonists

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11401246 - Triazole glycolate oxidase inhibitors (2022-08-02),

2. 10206931 - Therapeutic compounds and uses thereof (2019-02-19),

3. 9522920 - Bromodomain inhibitors and uses thereof (2016-12-20),

4. 9505767 - Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors (2016-11-29),

5. 9149465 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2015-10-06),

6. 8927551 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2015-01-06),

7. 8796261 - Bromodomain inhibitors and uses thereof (2014-08-05),

8. 8765735 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2014-07-01),

9. 8546422 - Azaindole derivatives as CRTH2 receptor antagonists (2013-10-01),

10. 8518964 - Tricyclic compounds useful as inhibitors of kinases (2013-08-27),

11. 7618979 - Pyridopyrrolizine and pyridoindolizine derivatives (2009-11-17),

12. 7582633 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2009-09-01),

13. 7429666 - Pyridine analogs as C5a antagonists (2008-09-30),

14. 7163932 - Aryldifluoromethylphosphonic acids for treatment of diabetes (2007-01-16),

15. 7144913 - Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists (2006-12-05),

Title: Yves Leblanc: Pioneering Inventor from Kirkland, CA

Introduction: Yves Leblanc is a renowned inventor hailing from Kirkland, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Yves Leblanc holds several patents in the areas of artificial intelligence, renewable energy, and sustainable transportation, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: Throughout his illustrious career, Yves Leblanc has worked with leading tech companies to develop cutting-edge solutions that have revolutionized industries and improved the lives of many.

Collaborations: Yves Leblanc has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and creativity in all his projects.

Conclusion: Yves Leblanc's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazing inventor in Kirkland, CA, and beyond.